Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89757 | 0.89 | PPIA (0.37) | CTSLCTSKMEN1MAPK1KMT2A | |
| SCHEMBL2809077 | 0.86 | P2RX7 (0.41) | CTSLCTSKMEN1MAPK1KMT2A | |
| SCHEMBL1667225 | 0.84 | CTSL (0.39) | USP2SMN1; SMN2CTSLCTSDCTSB | |
| SCHEMBL19388519 | 0.84 | USP2 (0.37) | USP2SMN1; SMN2CTSLCTSDCTSB | |
| SCHEMBL3022379 | 0.84 | CA12 (0.37) | USP2SMN1; SMN2CTSLCTSDCTSB | |
| SCHEMBL14851185 | 0.83 | CTSL (0.36) | USP2SMN1; SMN2CTSLCTSDCTSB | |
| SCHEMBL9898935 | 0.82 | P2RX7 (0.34) | CTSLCTSKMEN1MAPK1KMT2A | |
| SCHEMBL3019001 | 0.82 | CTSL (0.35) | USP2SMN1; SMN2CTSLCTSDCTSB | |
| SCHEMBL1692918 | 0.82 | CTSL (0.38) | USP2SMN1; SMN2CTSLCTSDCTSB | |
| SCHEMBL3372646 | 0.81 | CTSK (0.35) | USP2SMN1; SMN2CTSLCTSDCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | disclosed |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-11261191-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | ERBB2, MERTK, ABL1 | USP2 2420/4885SMN1; SMN2 3371/4885CTSL 3481/4885 |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | USP2 2420/4885SMN1; SMN2 3371/4885CTSL 3481/4885 |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | ERBB2, MERTK, ABL1 | USP2 2420/4885SMN1; SMN2 3371/4885CTSL 3481/4885 |
| US-11261191-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | MET, RET, ERBB2 | USP2 2275/4885SMN1; SMN2 2945/4885CTSL 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.